Search alternatives:
- Subject ("Proprotein Convertases subtilisin/kexin") »
Loading…
Semysinthetic biflavonoid Morelloflavone-7,4′,7″,3‴,4‴-penta-O-butanoyl is a more potent inhibitor of Proprotein Convertases Subtilisin/Kexin PC1/3 than Kex2 and Furin
de Souza, Aline Aparecida, de Andrade, Débora Martins, Siqueira, Fábio da Silva, Di Iorio, Juliana Fortes, Veloso, Marcia Paranho, Coelho, Camila de Morais, Viegas Junior, Claudio, Gontijo, Vanessa Silva, dos Santos, Marcelo Henrique, Meneghetti, Maria Cecília Zorél, Nader, Helena Bonciani, Tersariol, Ivarne Luis dos Santos, Juliano, Luiz, Juliano, Maria Aparecida, Judice, Wagner Alves de Souza
Published in Biochimica et biophysica acta. General subjects (01.12.2021)
Published in Biochimica et biophysica acta. General subjects (01.12.2021)
Get full text
Journal Article
Loading…
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Desai, Nihar R., Kohli, Payal, Giugliano, Robert P., O’Donoghue, Michelle L., Somaratne, Ransi, Zhou, Jing, Hoffman, Elaine B., Huang, Fannie, Rogers, William J., Wasserman, Scott M., Scott, Robert, Sabatine, Marc S.
Published in Circulation (New York, N.Y.) (27.08.2013)
Published in Circulation (New York, N.Y.) (27.08.2013)
Get full text
Journal Article
Loading…
Loading…
Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population—Brief Report
Xia, Vivian Q., Ong, Chui Mei, Zier, Lucas S., MacGregor, John S., Wu, Alan H.B., Chorba, John S.
Published in Arteriosclerosis, thrombosis, and vascular biology (01.02.2023)
Published in Arteriosclerosis, thrombosis, and vascular biology (01.02.2023)
Get full text
Journal Article
Loading…
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Watts, Gerald F, Chan, Dick C, Somaratne, Ransi, Wasserman, Scott M, Scott, Rob, Marcovina, Santica M, Barrett, P Hugh R
Published in European heart journal (14.07.2018)
Published in European heart journal (14.07.2018)
Get full text
Journal Article
Loading…
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Giugliano, Robert P., Pedersen, Terje R., Saver, Jeffrey L., Sever, Peter S., Keech, Anthony C., Bohula, Erin A., Murphy, Sabina A., Wasserman, Scott M., Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S.
Published in Stroke (1970) (01.05.2020)
Published in Stroke (1970) (01.05.2020)
Get full text
Journal Article
Loading…
Antisense‐mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first‐in‐human randomized, placebo‐controlled trial
Poelgeest, Eveline P., Hodges, Michael R., Moerland, Matthijs, Tessier, Yann, Levin, Arthur A., Persson, Robert, Lindholm, Marie W., Dumong Erichsen, Kamille, Ørum, Henrik, Cohen, Adam F., Burggraaf, Jacobus
Published in British journal of clinical pharmacology (01.12.2015)
Published in British journal of clinical pharmacology (01.12.2015)
Get full text
Journal Article
Loading…
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs
Virani, Salim S., Akeroyd, Julia M., Nambi, Vijay, Heidenreich, Paul A., Morris, Pamela B., Nasir, Khurram, Michos, Erin D., Bittner, Vera A., Petersen, Laura A., Ballantyne, Christie M.
Published in Circulation (New York, N.Y.) (20.06.2017)
Published in Circulation (New York, N.Y.) (20.06.2017)
Get full text
Journal Article
Loading…
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Marston, Nicholas A., Gurmu, Yared, Melloni, Giorgio E.M., Bonaca, Marc, Gencer, Baris, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Roselli, Carolina, Lubitz, Steven A., Ellinor, Patrick T., O’Donoghue, Michelle L., Giugliano, Robert P., Ruff, Christian T., Sabatine, Marc S.
Published in Circulation (New York, N.Y.) (19.05.2020)
Published in Circulation (New York, N.Y.) (19.05.2020)
Get full text
Journal Article
Loading…
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Stiekema, Lotte C A, Stroes, Erik S G, Verweij, Simone L, Kassahun, Helina, Chen, Lisa, Wasserman, Scott M, Sabatine, Marc S, Mani, Venkatesh, Fayad, Zahi A
Published in European heart journal (01.09.2019)
Published in European heart journal (01.09.2019)
Get full text
Journal Article
Loading…
Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Kwakernaak, Arjan J., Lambert, Gilles, Slagman, Maartje C.J., Waanders, Femke, Laverman, Gozewijn D., Petrides, Francine, Dikkeschei, Bert D., Navis, Gerjan, Dullaart, Robin P.F.
Published in Atherosclerosis (01.02.2013)
Published in Atherosclerosis (01.02.2013)
Get full text
Journal Article
Loading…
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Fitzgerald, Kevin, Frank-Kamenetsky, Maria, Shulga-Morskaya, Svetlana, Liebow, Abigail, Bettencourt, Brian R, Sutherland, Jessica E, Hutabarat, Renta M, Clausen, Valerie A, Karsten, Verena, Cehelsky, Jeffrey, Nochur, Saraswathy V, Kotelianski, Victor, Horton, Jay, Mant, Timothy, Chiesa, Joseph, Ritter, James, Munisamy, Malathy, Vaishnaw, Akshay K, Gollob, Jared A, Simon, Amy
Published in The Lancet (British edition) (04.01.2014)
Published in The Lancet (British edition) (04.01.2014)
Get full text
Journal Article
Loading…
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Ballantyne, Christie M., Neutel, Joel, Cropp, Anne, Duggan, William, Wang, Ellen Q., Plowchalk, David, Sweeney, Kevin, Kaila, Nitin, Vincent, John, Bays, Harold
Published in The American journal of cardiology (01.05.2015)
Published in The American journal of cardiology (01.05.2015)
Get full text
Journal Article
Loading…
Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
Cammisotto, Vittoria, Baratta, Francesco, Castellani, Valentina, Bartimoccia, Simona, Nocella, Cristina, D’Erasmo, Laura, Cocomello, Nicholas, Barale, Cristina, Scicali, Roberto, Di Pino, Antonino, Piro, Salvatore, Del Ben, Maria, Arca, Marcello, Russo, Isabella, Purrello, Francesco, Carnevale, Roberto, Violi, Francesco, Pastori, Daniele, Pignatelli, Pasquale
Published in International journal of molecular sciences (03.07.2021)
Published in International journal of molecular sciences (03.07.2021)
Get full text
Journal Article
Loading…
Proprotein convertase subtilisin/kexin type 9
Picard, Cynthia, Poirier, Alexandre, Bélanger, Stéphanie, Labonté, Anne, Auld, Daniel, Poirier, Judes
Published in PloS one (22.08.2019)
Published in PloS one (22.08.2019)
Get full text
Journal Article
Loading…
High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies
Qiu, Chengfeng, Zhou, Quan, Li, Xiaohui, Zhang, Zhen, Zeng, Pingyu, Cao, Zeng, Pan, Bingjie, Li, Xiaogang, Chen, Alex F.
Published in Medicine (Baltimore) (01.12.2017)
Published in Medicine (Baltimore) (01.12.2017)
Get full text
Journal Article
Loading…
Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis
Farmakis, Ioannis, Doundoulakis, Ioannis, Pagiantza, Areti, Zafeiropoulos, Stefanos, Antza, Christina, Karvounis, Haralambos, Giannakoulas, George
Published in Journal of cardiovascular pharmacology (01.03.2021)
Published in Journal of cardiovascular pharmacology (01.03.2021)
Get more information
Journal Article
Loading…
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
Lin, Po-Lin, Wu, Yen-Wen, Lin, Chao-Feng, Yeh, Hung-I, Chang, Wei-Ting, Charng, Min-Ji, Huang, Po-Hsun, Lin, Chih-Chan, Lin, Tsung-Hsien, Lin, Wei-Wen, Hsieh, I-Chang, Kuo, Feng-Yu, Chen, Ching-Pei, Li, Yi-Heng
Published in Journal of Atherosclerosis and Thrombosis (01.09.2023)
Published in Journal of Atherosclerosis and Thrombosis (01.09.2023)
Get full text
Journal Article
Loading…
Loading…
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways
Cameron, Jamie, Bogsrud, Martin P., Tveten, Kristian, StrØm, Thea Bismo, Holven, Kirsten, Berge, Knut Erik, Leren, Trond P.
Published in Translational research : the journal of laboratory and clinical medicine (01.08.2012)
Published in Translational research : the journal of laboratory and clinical medicine (01.08.2012)
Get full text
Journal Article